Subcutaneous Treatment With Icatibant for Acute Attacks of Hereditary Angioedema (HAE)

Inclusion Criteria: * Age above 18 years; * Documented diagnosis of HAE Type I or II (confirmed C1-INH deficiency); * Current edema in the cutaneous, abdominal and/or laryngeal areas; * Current edema moderate to severe according to the investigator's Symptom Score. Exclusion Criteria: * Diagnosis of angioedema other than HAE, * Participation in a clinical trial of another investigational medicinal product (IMP)within the past month * Treatment with any pain medication since onset of the current angioedema attack * Treatment with replacement therapy, including C1-INH products, less than 3 days before onset of the current angioedema attack * Treatment with Tranexamic acid replacement therapy within a week before onset of the current angioedema attack * Treatment with ACE inhibitors * Contraindications for Tranexamic acid * Evidence of coronary artery disease based on medical history or Screening examination in particular unstable angina pectoris or severe coronary heart disease * Congestive heart failure (class 3 and 4) * Serum creatinine level of ≥ 250 μmol/L * Serious concomitant illness that the investigator considered to be a contraindication for participation in the trial * Pregnancy (as assessed prior to treatment) and/or breast-feeding